Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Kayali, F. [1 ]
Janjua, M. A. [1 ]
Laber, D. A. [1 ]
Miller, D. M. [1 ]
Day, J. M. [1 ]
Kloecker, G. H. [1 ]
机构：
[1] Univ Louisville, Louisville, KY 40292 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19077
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase II trial of second-line erlotinib and digoxin for nonsmall cell lung cancer (NSCLC)
    Kayali, Fadi
    Janjua, Muhamad A.
    Laber, Damian A.
    Miller, Donald
    Kloecker, Goetz H.
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2011, 3 : 9 - 13
  • [2] A phase II trial of second-line erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC)
    Iyengar, Puneeth
    Kavanagh, Brian D.
    Smith, Irma
    Ahn, Chul
    Gerber, David E.
    Dowell, Johnathan
    Hughes, Randall S.
    Abdulrahman, Ramzi
    Camidge, D. Ross
    Gaspar, Laurie E.
    Doebele, Robert Charles
    Bunn, Paul A.
    Choy, Hak
    Timmerman, Robert D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Multicenter phase II trial of motexafin gadolinium (MGd) and pemetrexed (PEM) for second-line treatment in patients with non-small cell lung cancer (NSCLC)
    Edelman, Martin J.
    Otterson, Gregory A.
    Leach, Joseph
    Malpass, Thomas
    Salgia, Ravi
    Jones, Dennie
    Szakacs, Nancy
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S455 - S455
  • [4] Phase II study of cabazitaxel as second-line therapy in stage IV non-small cell lung cancer (NSCLC).
    Das, Devika
    Robert, Francisco
    Bordoni, Rodolfo
    Grant, Stefan C.
    Saleh, Mansoor N.
    Reddy, Vishnu
    Jerome, Mary
    Miley, Debi
    Singh, Karen P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A randomized phase II trial of erlotinib or erlotinib and bevacizumab in patients with advanced EGFR mutant non-small cell lung cancer (NSCLC)
    Stinchcombe, T. E.
    Janne, P. A.
    Wang, X.
    Bertino, E. M.
    Weiss, J. M.
    Bazhenova, L.
    Gu, L.
    Lau, C. J.
    Paweletz, C. P.
    Jaslowski, A. J.
    Gerstner, G. J.
    Baggstrom, M. Q.
    Graziano, S. L.
    Beardenlii, J.
    Vokes, E. E.
    ANNALS OF ONCOLOGY, 2018, 29 : 522 - 522
  • [6] GEFITINIB, ERLOTINIB AND CHEMOTHERAPY AS SECOND-LINE TREATMENT FOR PATIENT WITH ADVANCED NON-SMALL LUNG CANCER (NSCLC)
    Yang, M.
    Tan, E. C.
    Chen, Y.
    VALUE IN HEALTH, 2016, 19 (07) : A885 - A885
  • [7] Erlotinib in non-small cell lung cancer (NSCLC) in Germany - A cost-saving second-line treatment option?
    Gabriel, A.
    Pirk, O.
    Kotowa, W.
    VALUE IN HEALTH, 2006, 9 (06) : A278 - A278
  • [8] Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer
    Choong, Nicholas W.
    Mazcer, Ann M.
    Hoffman, Philip C.
    Rudin, Charles M.
    Winegarden, Jerome D., III
    Villano, J. Lee
    Kozloff, Mark
    Wade, James L., III
    Sciortino, David F.
    Szeto, Livia
    Vokes, Everett E.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 245 - 251
  • [9] Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial
    Serke, M
    Schoenfeld, N
    Loddenkemper, R
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1211 - 1216
  • [10] Phase II trial of temozolomide and irinotecan as second-line treatment for advance non-small cell lung cancer
    Choong, N
    Mauer, A
    Hoffman, P
    Ma, PR
    Cohen, E
    Rudin, C
    Kozloff, M
    Sciortino, D
    Szeto, L
    Vokes, E
    LUNG CANCER, 2005, 49 : S241 - S241
12345